Marialuisa Partisani

Strasbourg, 67091, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.

Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.

Journal: EBioMedicine
Published: June 02, 2021

Prospective evaluation of blood Epstein-Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas.

Prospective evaluation of blood Epstein-Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas.

Journal: AIDS (London, England)
Published: March 22, 2021

Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France.

Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France.

Journal: Emerging infectious diseases
Published: December 02, 2020

A FcɣRIIa polymorphism has a HLA-B57 and HLA-B27 independent effect on HIV disease outcome.

A FcɣRIIa polymorphism has a HLA-B57 and HLA-B27 independent effect on HIV disease outcome.

Journal: Genes and immunity
Published: March 25, 2020

Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV.

Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV.

Journal: AIDS (London, England)
Published: December 14, 2019

Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.

Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.

Journal: The Journal of infectious diseases
Published: April 20, 2019

Epstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era.

Epstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era.

Journal: AIDS (London, England)
Published: April 05, 2019

Treatment as prevention enrolling at least 75% of individuals on ART will be needed to significantly reduce HIV prevalence in a HIV cohort.

Treatment as prevention enrolling at least 75% of individuals on ART will be needed to significantly reduce HIV prevalence in a HIV cohort.

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Published: April 04, 2019

Distribution and reduction magnitude of HIV-DNA burden in CD4+ T cell subsets depend on art initiation timing.

Distribution and reduction magnitude of HIV-DNA burden in CD4+ T cell subsets depend on art initiation timing.

Journal: AIDS (London, England)
Published: February 10, 2018

Trends in the risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France: Impact of gender and immune status.

Trends in the risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France: Impact of gender and immune status.

Journal: PloS one
Published: December 13, 2017

Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era.

Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era.

Journal: AIDS (London, England)
Published: September 20, 2017

Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs.

Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs.

Journal: The Journal of antimicrobial chemotherapy
Published: September 13, 2017
Showing 1-12 of 25

Last Updated: 09/26/2026